Subscribe
shutterstock_1533140117_michael_vi
Michael Vi / Shutterstock.com
23 October 2019Big PharmaSaman Javed

10x Genomics to pay Becton Dickinson $25m settlement

US biotechnology company 10x Genomics is to pay its competitor, Becton Dickinson, $25 million as part of a deal to end worldwide patent infringement litigation between the companies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
US med-tech secures victory in drug transfer system dispute
25 August 2022   Illinois court rules company’s syringe to drug vial system doesn’t infringe | System’s components can be used for other purposes.
Americas
10x Genomics sued over cell research tools
20 November 2018   Genome sequencing company 10x Genomics has been accused of infringing 11 patents covering cell research and analysis tools.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

The Quintara decision: Defining trade secrets in federal cases
To disclose or not: Pharma patents face new AI reality
Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech